Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05417594 · ClinicalTrials.gov registry record · Phase 1

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

A Phase 1 study of Advanced Solid Malignancies, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
695
Enrollment target
20
Study locations

NCT05417594 is a Phase 1 study of Advanced Solid Malignancies that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 695 participants, above the 130-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (435% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05417594, a Phase 1 study of Advanced Solid Malignancies, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
695 participants
Enrollment target
20
Study locations

Study Summary

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.

Conditions Studied

Advanced Solid Malignancies

Interventions

  • DRUG AZD9574
  • DRUG Trastuzumab Deruxtecan (T-DXd)
  • DRUG Temozolomide (TMZ)
  • DRUG [11C]AZ1419 3391
  • DRUG Datopotamab Deruxtecan (Dato-DXd)

Study Locations (20)

Other

  • Research Site - Camperdown
  • Research Site - Darlinghurst
  • Research Site - Melbourne
  • Research Site - Randwick
  • Research Site - Bayern
  • Research Site - Berlin
  • Research Site - Heidelberg
  • Research Site - Mainz
  • Research Site - Seoul

California

  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - San Francisco

New York

  • Research Site - New York
  • Research Site - New York

Texas

  • Research Site - Houston
  • Research Site - San Antonio

Illinois

  • Research Site - Chicago

Massachusetts

  • Research Site - Boston

Oregon

  • Research Site - Portland

Virginia

  • Research Site - Richmond

Trial Details

FieldValue
Enrollment Target 695 participants
Start Date 2022-06-24
Est. Completion 2027-08-11
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05417594

The ClinicalTrials.gov registry entry for NCT05417594 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 695 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 130-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (435% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Malignancies appearing as the primary indexed condition, and to 5 interventions - of which AZD9574 is the first listed.

NCT05417594 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT05417594 about?

NCT05417594 is a clinical study titled "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies". This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.

What is the current status of trial NCT05417594?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 695 participants. The study started on 2022-06-24. Estimated completion is 2027-08-11.

What conditions does trial NCT05417594 study?

This clinical trial studies the following conditions: Advanced Solid Malignancies.

What interventions are being tested in trial NCT05417594?

The interventions under investigation include: AZD9574 (DRUG), Trastuzumab Deruxtecan (T-DXd) (DRUG), Temozolomide (TMZ) (DRUG), [11C]AZ1419 3391 (DRUG), Datopotamab Deruxtecan (Dato-DXd) (DRUG).

Who is sponsoring clinical trial NCT05417594?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05417594 being conducted?

This trial has 20 study locations across California, Illinois, Massachusetts, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Malignancies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Malignancies

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.